People: Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

13 Sep 2019
Change (% chg)

$-0.09 (-0.28%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Spencer, Sarah 

Ms. Sarah Spencer is Vice President, Corporate Communications of the company. Sarah has more than 20 years of experience in healthcare and life sciences communications. She joins Audentes from GlaxoSmithKline (GSK) where she was most recently Head, US Corporate Communications. Sarah spent 13 years at GSK working in a variety of global communications roles both in the UK and the US where she had responsibility for corporate media relations, financial communications, crisis communications, reputation management, and product and pipeline communications. Sarah has worked directly with CEO & C-suite executives extensively. Prior to GSK, Sarah worked at Elan Pharmaceuticals (now Perrigo Company) where she led the launch communications for Tysabri ® and helped to build the profile of the company's neurology pipeline. Sarah also worked at Berry PR, a healthcare public relations agency, where she developed and executed communications strategies and campaigns for small and emerging biotech clients. Sarah began her career at Rite Aid Corporation where she served for eight years as a lead media spokesperson handling numerous high-profile issues and crises. Sarah holds a B.S. in Communications & Psychology from the State University of New York at Buffalo.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --